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Background/aim: Depression and anxiety are prevalent symptoms in kidney transplant patients. We aimed to evaluate the frequency
and the severity of depression and anxiety symptoms in kidney transplant recipients using the Beck Depression Inventory (BDI)
and Beck Anxiety Inventory (BAI). The data were compared between the patients on CNI-based and mTORi-based maintenance
immunosuppressive regimens.
Materials and methods: A total of 94 kidney transplant patients were enrolled in the study after exclusion of the patients already taking
neuropsychiatric medications or unwilling to participate in the study. Participants were asked to self-report the inventories.
Results: Analysis of data showed that 62 (66%) recipients had BDI scores that indicated depression. The patients on CNI-based regimens
(n = 74) had increased total BDI scores compared those on mTORi-based regimens [18 (8.75–28) vs. 6 (5.25–14.25), respectively, P <
0.001]. Regarding BAI scores, 79 patients (84%) had prominent anxiety symptoms. The patients on CNI-based regimens had significantly
increased total BAI scores compared to those on mTORi-based regimens [21 (13–30.50) vs. 10.50 (8.25–14.75), respectively, P < 0.001].
Conclusion: Our results identified fewer side effects of mTORi-based maintenance immunosuppressive regimens regarding depression
and anxiety symptoms compared to CNI-based regimens in kidney transplant patients.
Key words: Anxiety, calcineurin inhibitors, depression, kidney transplantation, mammalian target of rapamycin inhibitors

1. Introduction
Kidney transplantation is the best treatment modality
for patients having end-stage renal disease and enhances
their quality of life (1). The recipients remain on life-long
maintenance immunosuppressive therapies including
frequently a corticosteroid, an antiproliferative agent,
and either a calcineurin inhibitor (CNI) or a mammalian
target of rapamycin inhibitor (mTORi) (2). The advance of
CNIs in the early 1980s provided improvements in shortterm allograft survival by reducing acute rejection rates.
However, they exhibited serious adverse effects such as
new-onset diabetes mellitus, chronic allograft nephropathy,
and neurotoxicity in long-term follow -up (3,4). Hence, a
relatively newer immunosuppressive group, mTORis, has
been increasingly used as a part of CNI-withdrawal or
CNI-avoidance regimens in kidney recipients (5).
During the transplantation process, physicians mainly
focus on allograft functions as well as short- and long-term
complications of immunotherapy. However, accumulated
data show that this particular population also has
considerably increased prevalence of psychiatric disorders
* Correspondence: ebrugokoguz@hotmail.com

including cognitive (6) and affective dysfunctions (7). In
the medical literature, the neuropsychiatric adverse effects
of corticosteroids have been well established (8). However,
there has been a limited number of clinical studies
exploring the impact of CNIs and mTORis on psychiatric
symptoms in solid organ transplant recipients (6,9,10). In
the present study, we aimed to evaluate the frequency and
the severity of depression and anxiety symptoms in kidney
transplant patients by using self-report inventories and to
explore the associations of CNI-based and mTORi-based
regimens with the results of inventories.
2. Materials and methods
This single-center observational study was performed at
Dışkapı Yıldırım Beyazıt Education and Research Hospital,
Ankara, Turkey. The study protocol was in accordance with
the Helsinki Declaration and the local ethics committee
approved it.
2.1. Study population
All living-donor or deceased-donor kidney transplant
patients (between 18 and 65 years of age, transplanted at
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least 1 year ago) presenting to our outpatient nephrology
clinic for follow-up treatment were invited to the study. The
ones who were unwilling to participate in the study (n = 15)
and/or the ones already taking psychiatric medications (n
= 16) were excluded. Finally, 94 patients were enrolled in
the study. They were on maintenance immunosuppression
with either CNI-based (n = 74) or mTORi-based
(n = 20) regimens. As a part of their maintenance
immunosuppressive regimens, patients were also receiving
prednisolone (5 mg per day) and an antiproliferative agent
(mycophenolate at a dosage of 1000–2000 mg per day or
azathioprine at a dosage of 50–100 mg per day). All the
patients on mTORi-based regimens had been previously
on CNI-based regimens, but their therapies were switched
to mTORi as a CNI-avoidance strategy due to adverse
effects such as nephrotoxicity, hirsutism, and gingival
hypertrophy. All of these 20 patients were on mTORibased regimens at least for 6 months. The dosages of CNI
(either tacrolimus or cyclosporine (CsA)) and mTORi
(either sirolimus or everolimus) were being adjusted
according to blood concentrations.
2.2. Data collection tools
Sociodemographic features of the patients including age,
sex, and marital and employment status were noted based
on patients’ charts and interviews. The type and time on
dialysis before transplantation, transplantation history
including donor type, presence of acute rejection episode,
time since transplantation, current immunosuppressive
medications, and concentrations of serum creatinine at
the last visit were recorded. Each patient was assessed by
clinical interview and the Beck Anxiety Inventory (BAI)
and Beck Depression Inventory (BDI).
2.3. Beck Depression Inventory
The BDI is a self-report inventory used to measure the
severity of depression. The questionnaire includes 21
multiple-choice items that describe specific depressive
symptoms over the past week. Each item is scored on a
scale from 0 to 3 and the sum of these gives the total BDI
score. Patients having <10 total BDI score are accepted as
normal. A total BDI score of ≥10 indicates symptomatic
patients, 10–18 indicates mild depression, 19–29 indicates
moderate depression, and ≥30 indicates severe depression
(11). The validity and reliability of the BDI in Turkish
population were evaluated by Hisli (12).
2.4. Beck Anxiety Inventory
The BAI is a self-report inventory developed by Beck et al.
(13) to determine the frequency of anxiety symptoms. It is
composed of 21 items. Each item is scored on a scale from
0 to 3 and the sum of these gives the total BAI score. Scores
of 0–7 were accepted as negative symptomatology for
anxiety. Scores of 8–15 show mild, scores of 16–25 show
moderate, and scores of 26–63 show severe anxiety (13).
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The reliability and validity of the BAI were established in
Turkey (14).
2.5. Statistical analysis
Statistical analysis was conducted using SPSS 18 (SPSS Inc.,
Chicago, IL, USA). Normality of distribution was tested
by the Kolmogorov–Smirnov test and histograms for
continuous variables. Normally distributed variables were
expressed as mean ± standard deviation and the others are
presented as median and interquartile ranges (the range
of values lying between the 25th and 75th percentiles).
The Student t-test or Mann–Whitney U test was used for
comparisons of two groups. Categorical variables were
shown as frequency and percentages and were assessed by
using the chi-square test or Fisher exact test as appropriate.
All P-values were calculated as two-sided, and P < 0.05 was
considered as significant.
3. Results
Demographic characteristics of the participants are
presented in Table 1. The mean age of the patients was
42.84 ± 10.23 years. Of the patients, 74.5% were male,
56.4% were married, and 48.9% were employed.
There was no significant difference between group
I (CNI-based regimen, n = 74 patients) and group II
(mTORi-based regimen, n = 20) with regard to sex, age,
marital status, employment status, dialysis history, or
transplantation history. There was a trend toward higher
serum creatinine values in group II patients (Table 1).
Analysis of the data obtained from the BDI showed
that 62 patients (66%) had total scores of ≥10 and were
rated as symptomatic for depression; 27 had mild, 21 had
moderate, and 14 had severe levels of depression. The
mean BDI score was found to be significantly higher in
group I compared to group II (P < 0.001). Fifty-six patients
(75.6%) had depression (total BDI score of ≥10) in group
I (21 patients with mild, 21 with moderate, and 14 with
severe depression scores); 6 patients (30%) had depression
(total BDI score of ≥10) in group II (all with mild levels of
depression scores) (P < 0.001) (Table 1). The prevalence
of moderate and severe levels of depression was higher
among CNI users (P = 0.015) (Table 1).
Analysis of the data collected with the BAI showed
that 79 patients (84%) had prominent anxiety symptoms
(total BAI score of >7); 31 patients had mild, 26 moderate,
and 22 severe levels anxiety. The mean anxiety score was
significantly higher in group I than in group II (P < 0.001).
However, the prevalence of prominent anxiety symptoms
was similar in the two groups (P = 0.299). Sixty-four
patients (86.5%) had prominent anxiety (18 patients with
mild, 24 with moderate, and 22 with severe anxiety scores)
in group I; 15 patients (75.0%) had prominent anxiety (13
patients with mild and 2 with moderate anxiety scores) in
group II (Table 1). The prevalence of moderate and severe
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Table 1. Demographic features of study population.
Total group
(n = 94)

Patients on
CNI-based regimens
(n = 74)

Patients on
mTORi-based regimens
(n = 20)

Sex (male, n,%)

70 (74.5%)

56 (75.7%)

14 (70%)

0.606

Age (years)

42.84 ± 10.23

42.70 ± 10.72

43.35 ± 8.43

0.803

Marital status (married, n,%)

53 (56.4%)

42 (56.8%)

11 (55%)

0.888

Employment status (employed, n,%)

46 (48.9%)

34 (45.9%)

12 (60%)

0.265

Hemodialysis

61 (64.9%)

49 (66.2%)

12 (60%)

0.605

Peritoneal dialysis

33 (35.1%)

25 (33.8%)

8 (40%)

Time on dialysis (months)

21.5 (9–36)

20 (8–36)

30 (12.5–47.0)

0.062

Living donor (n,%)

50 (53.2%)

39 (52.7%)

11 (55.0%)

0.855

Rejection episode (n,%)

21 (22.3%)

19 (25.7%)

2 (10%)

0.225

Time since transplantation (months)

72 (41–97)

66 (36–102)

72 (60–93)

0.539

Serum creatinine (mg/dL)

1.5 (1.2–2.0)

1.5 (1.13–2.0)

1.65 (1.5–2.0)

0.055

Total BDI scores

15 (7–26)

18 (8.75–28)

6 (5.25–14.25)

<0.001

Total BDI scores ≥10 (n, %)

62 (66%)

56 (75.6%)

6 (30%)

<0.001

Total BDI scores 10–18 (n ,%)

27 (43.5%)

21 (37.5%)

6 (100%)

0.015*

Total BDI scores 19–29 (n, %)

21 (33.9%)

21 (37.5%)

-

Total BDI scores ≥30 (n, %)

14 (22.6%)

14 (25.0%)

-

Total BAI scores

18 (10.75–25)

21 (13–30.50)

10.50 (8.25–14.75)

<0.001

Total BAI scores >7 (n, %)

79 (84%)

64 (86.5%)

15 (75.0%)

0.299

31 (39.2%)

18 (28.1%)

13 (86.7%)

Total BAI scores 16–25 (n, %)

26 (32.9%)

24 (37.5%)

2 (13.3%)

Total BAI scores 23–63 (n, %)

22 (27.8%)

22 (34.4%)

-

P

Dialysis history before transplantation
Dialysis type (n,%)

Transplantation history

BDI results

BAI results

Total BAI scores 8–15 (n, %)

<0.001*

CNI, Calcineurin inhibitors; mTORi, mammalian target of rapamycin inhibitor; BDI, Beck Depression Inventory; BAI, Beck Anxiety
Inventory.
*P-value belongs to chi-square testing that compares the frequencies of three levels of depression/anxiety between patients on CNIbased and mTORi-based regimens.

anxiety levels was higher among CNI users (P < 0.001)
(Table 1).
When the patients on CNI-based regimens were
divided into two groups as those on tacrolimus (n = 41) and
those on CsA (n = 33), the groups were similar in regard to

total BDI and BAI scores, and the prevalence of depression
(total BDI score ≥10 ) and anxiety (total BAI score >7).
However, the patients on tacrolimus had moderate and
severe levels of depression and anxiety symptoms (P < 0.05
for both) (Table 2).
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Table 2. Comparison of the BDI and BAI results between patients on tacrolimus and cyclosporine regimens.
Patients on CNI-based regimens
Patients on tacrolimus (n = 41)

Patients on cyclosporine (n = 33)

P

Total BDI score

24 (10–35)

15 (8–24.5)

0.073

Total BDI scores ≥10 (n, %)

31 (75.6%)

25 (75.8%)

0.988

Total BDI scores 10–18 (n, %)

9 (29.0%)

12 (48.0%)

0.002*

Total BDI scores 19–29 (n, %)

8 (25.8%)

13 (52.0%)

Total BDI scores ≥30 (n, %)

14 (45.2%)

-

Total BAI score

22 (12.5–40)

20 (13–23.50)

0.129

Total BAI scores >7 (n, %)

34 (82.9%)

30 (90.9%)

0.496

Total BAI scores 8–15 (n, %)

7 (20.6%)

11 (36.7%)

0.004*

Total BAI scores 16–25 (n, %)

9 (26.5%)

15 (50.0%)

Total BAI scores 23–63 (n, %)

18 (52.9%)

4 (13.3%)

BDI results

BAI results

CNI, Calcineurin inhibitors; BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory.
*P-value belongs to chi-square testing that compares the frequencies of three levels of depression/anxiety between patients on CNIbased and mTORi-based regimens.

When the patients with total BDI score of ≥10 (n = 62)
were compared with those with total BDI scores of <10 (n
= 32), the age (41.95 ± 9.60 vs. 44.56 ± 11.33, respectively, P
= 0.243), male sex [46 (74.2%) vs. 24 (75.0%), respectively,
P = 0.932], rate of marriage [31 (50%) vs. 22 (68.7%),
respectively, P = 0.082], time since transplantation [57
(36–96.5) vs. 74 (58.5–99), respectively, P = 0.140],
and rate of employment [36 (58.1%) vs. 12 (37.5%),
respectively, P = 0.059] were similar. However, patients
with BDI scores indicating depression (total BDI score
≥10) had more commonly performed hemodialysis as a
dialysis modality before transplantation [45 (72.6%) vs.
16 (50.0%), respectively, P = 0.03] and had a longer time
on dialysis before transplantation [27 (17.5–38) vs. 9.5 (5–
17.25), respectively, P < 0.001], a higher rate of cadaveric
donors [39 (62.9%) vs. 5(15.6%), respectively, P < 0.001],
and an increased number of acute rejection episodes [20
(32.3%) vs. 1 (3.1%), respectively, P = 0.001].
When the patients with prominent anxiety (n = 79)
(total BAI score >7) symptoms were compared with
those with total BAI scores of <7 (n = 15), the age (43.18
± 9.93 vs. 41.07 ± 11.94, respectively, P = 0.467), sex [58
(73.4%) vs. 12 (80%), respectively, P = 0.753], dialysis type
as hemodialysis [53 (67.1%) vs. 8 (53.3%), respectively,
P = 0.306], and time since transplantation [60 (40–96)
vs. 84 (48–110), respectively, P = 0.285] were similar.
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However, patients with prominent anxiety symptoms
(total BAI score of >7) had a lower rate of marriage [39
(49.4) vs. 14 (93.3%), respectively, P = 0.002], a lower rate
of employment [34 (43.0%) vs. 12 (80%), respectively, P =
0.009], a longer time on dialysis before transplantation [24
(10–36) vs. 5 (2–18), respectively, P < 0.001], a higher rate
of cadaveric donors [43 (54.4%) vs. 1 (6.7%), respectively,
P = 0.001], and an increased number of acute rejection
episodes [21 (26.6%) vs. zero, respectively, P = 0.020].
4. Discussion
In the present study, we observed that the total depression
and anxiety scores as well as the severity levels of the
diseases were increased in patients on CNI-based regimens
compared to those of the patients on mTORi-based
regimens. To the best of our knowledge, this is the first
study comparing the impacts of CNI-based and mTORibased regimens on depression and anxiety scores and
disease severity levels determined by using the BDI and
BAI. We found that 66% of our patients had total BDI scores
of ≥10 and 84% of them had total BAI scores of >7. These
were relatively higher scores compared to the other studies
that reported distinctive values for depression ranging from
20% to 75% and for anxiety ranging from 27% to 50% in
kidney transplant patients (15–18). The types of diagnostic
tools, the special characteristics of the study populations
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(socioeconomic situations, extremely low deceased
donor rates, and subsequently longer duration of dialysis
treatments in Turkey) could have affected the results.
In the medical literature, there have been limited and
conflicting results concerning the psychiatric effects of
immunosuppressive agents in patients with solid organ
transplantation. A small-sized study including nine hearttransplanted cases showed improved mood, memory, and
quality of life after switching from CNI-based regimens
to everolimus (10). On the other hand, the psychiatric
effects of immunosuppressive agents in kidney recipients
were investigated in a single study that yielded impaired
attention and memory in sirolimus and tacrolimus
users, while cyclosporine users had similar outcomes
compared to healthy volunteers (6). In our study, CNI
users had significantly increased total BDI and BAI
scores as compared to mTORi users. The understanding
of the physiological actions of calcineurin and/or mTORi
molecules could help in the interpretation of these
results. Calcineurin regulates the neurotransmission,
neuronal excitability, and plasticity in the amygdala
and provides normal mood reactions in human bodies.
Some researchers have suggested that it is involved in the
regulation of depressive behaviors (19), and antidepressive
agents develop their effects via calcineurin activation
(20). Experimental studies have shown that calcineurin
blockage increases depressive-like symptoms (21) and the
prevalence of depression and anxiety (22). Experimental
studies showed that mTORi signaling is needed for
hippocampus-dependent fear, long-term memory (23),
and the synthesis of brain-derived-neurotrophic factor
(BDNF), which is a growth factor secreted from the
hippocampus (24,25). Recently published data showed
alterations of BDNF synthesis in patients with depression
(26) and BDNF polymorphism in patients with anxiety
(27). An mTORi, CCI-779, resulted in euphoria followed
by melancholia (similar to a temporary bipolar disorder) in
one-fifth of patients with malignancy after administration
of a single dose (28). As a consequence, not only calcineurin
inhibition but also mTORi inhibition seems to be related
with depression and anxiety. The alterations in BDNF and
related growth factors in CNI and mTORi users might be
subject of further studies.
As general knowledge, tacrolimus more frequently
causes psychiatric and neurological symptoms than
cyclosporine (29). However, some authors showed similar
results for tacrolimus and cyclosporine (9), whereas some
others showed deteriorated results with tacrolimus (7). In
our study, although the frequency and total scores were
similar for the BDI and BAI, tacrolimus users were prone
to having more severe levels of symptoms.
We observed that marital status was similar between
the patients with BDI scores of ≥10 or <10, whereas

patients with prominent anxiety symptoms had lower
rates of marriage. Sayın et al. noted that marital status did
not affect the psychological status of transplanted patients
(30). However, Akman et al. reported a higher incidence of
depression in single patients (31). We thought that family
support is important for the mood of the patients. There
was a trend towards increased unemployment in patients
with BDI scores of ≥10 and a higher rate of unemployment
was observed in those with BAI scores of <7. In support
of this, a prior study showed that employment affects the
prevalence of depression, which appears more frequently
in people of low socioeconomic status (32). These data
suggest that unemployment may trigger either depression
or anxiety. In our study, the time on dialysis before
transplantation was longer in patients with depression and
anxiety, in line with the observations of other researchers
(33). The renal replacement modality was hemodialysis in
our patients with BDI scores of ≥10, whereas other authors
reported no difference in this regard (34). Similar to Parsei
et al. (35), we showed higher rates of deceased donors in
patients with depression and anxiety symptoms. Acute
rejection history was significantly higher in patients with
depression and anxiety. These findings suggest that fear of
rejection may be associated with depressive and anxiety
symptoms. One of our patients was retransplanted and
had severe levels of depression and anxiety symptoms.
A previous study showed a higher incidence of mental
disorders in retransplanted patients than in those with
a single liver transplantation (36). Further studies with
larger samples are needed to confirm our findings.
Studies have shown that patients who are depressed
are less likely to adhere to their medications (37,38). A
metaanalysis showed that depressed patients were 3-fold
more likely to be noncompliant to their medical regimen
than patients without depression (37). The results of
another study also suggested that psychological distress
such as anxiety and anger may lead to nonadherence to
drugs in adolescent renal transplant recipients (38). Since
decreased medication adherence causes organ rejections in
transplant recipients, it is very important to diagnose and
treat depression in a timely manner. Hence, we suppose
that renal transplant recipients should be screened for
depression and anxiety regularly and treated appropriately
to enhance their quality of life and treatment adherence
and to decrease morbidity.
Our study has some limitations. The cross-sectional
study design prevents us from establishing an exact
cause-and-consequence relation between drug groups
and depression and anxiety symptoms. The relatively
small number of patients on mTORi-based regimens was
a result of the primary choice of CNI-based regimens
in maintenance immunotherapy in kidney transplant
patients in our center.
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In conclusion, we demonstrated increased scores for
depression and anxiety by using self-reported inventories
in kidney transplant patients, particularly in those on CNIbased regimens. In clinical practice, physicians should also
consider the potential adverse effects of CNIs and mTORis

on depression and anxiety, besides their more well-known
adverse effects. Further studies are warranted to confirm
our results and to elucidate the possible underlying
mechanisms.
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